Literature DB >> 12659698

Beta-blockers and atrial natriuretic peptide (ANP) in hypertension.

C L Papadopoulos1, B A Kokkas, G A Anogiannakis.   

Abstract

Several studies (including ours) in patients with moderate hypertension indicate that beta-adrenergic blockers exert their antihypertensive action in part by increasing ANP secretion. There is also strong evidence that (beta 1- adrenergic receptors are mainly involved in this action. In this article we provide an overview on some of these studies.

Entities:  

Year:  2000        PMID： 12659698

Source DB:  PubMed          Journal:  Int J Immunopathol Pharmacol        ISSN： 0394-6320            Impact factor:   3.219


  3 in total

1.  Plasma atrial natriuretic peptide levels in essential hypertension after treatment with verapamil.

Authors:  B Kokkas; P Kotridis; M Karamouzis; I Kanonidis; G Sakadamis; G Dadous; S Haritos; P Kyriakoui; P C Papadopoulos; V Mirtsou-Fidani; C L Papadopoulos
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2002 Jan-Mar       Impact factor: 2.441

Review 2.  Atrial natriuretic peptide contributes to the antihypertensive action of many drugs.

Authors:  C L Papadopoulos; B A Kokkas
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2003 Jan-Mar       Impact factor: 2.441

3.  Plasma atrial natriuretic peptide in essential hypertension after treatment with terazocin.

Authors:  P Kotridis; B Kokkas; P Kyriakou; M Karamouzis; G Salpigidis; C Karantona; J Karadoumanis; T Ginis; O Goulis; P C Papadopoulos; C Vakalopoulos; G Sakantamis; A Dimitriadou; V Mirtsou-Fidani; C L Papadopoulos
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2003 Apr-Jun       Impact factor: 2.441
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.